Table 1.
General population characteristics.
| Author/Year | Study Period | Study Type | Patient Population, n | Gender, n (%) | Age, Median Years (Range) | Primary CRC Location, n (%) | CEA, Median ng/mL (Range) | CA 19.9, Median U/mL (Range) | Chemotherapy, n (%) | Radiotherapy, n (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | Right Colon | Left Colon | Rectum | No | Neoadjuvant | Adjuvant | No | Neoadjuvant | Adjuvant | |||||||
| Min et al./2008 | 1992–2004 | SC-RS | 6 | 3 (50.0) | 3 (50.0) | 58.2 a | 3 (50.0) | 3 (50.0) | 22.04 a | / | 0 | 0 | 6 (100) | 6 (100) | 0 | 0 | |
| Choi et al./2010 | 1993–2006 | SC-RS | 24 | 13 (54.2) | 11 (45.8) | 52 (27–78) a | 11 (45.8) | 4 (16.7) | 9 (37.5) | / | / | 1 (4.2) | 0 | 23 (95.8) | 24 (100) | 0 | 0 |
| Gagnière et al./2015 | 1997–2012 | SC-RS | 10 | / | / | / | / | / | / | / | / | 0 | / | / | / | / | / |
| Song et al./2016 | 2004–2013 | SC-RS | 16 | 12 (75.0) | 4 (25.0) | 61 (45–79) | 1 (6.2) | 8 (50.0) | 7 (43.8) | / | / | 0 | 0 | 16 (100) | / | / | / |
| Ogura et al./2017 | 2004–2013 | SC-RS | 16 | 5 (31.3) | 11 (68.7) | 58.5 (39–82) | 3 (18.8) | 11 (68.8) | 2 (12.4) | 8.3 (2.6–154.2) | 23.2 (6.4–313.3) | 0 | 4 (25.0) | 15 (93.8) | / | / | / |
| Bae et al./2018 | 1988–2009 | SC-RS | 49 | 29 (59.2) | 20 (40.8) | 57.5 ± 11.5 a | 6 (12.2) | 43 (87.8) | 0 | 23.7 ± 2.8 a | / | / | / | 47 (95.9) | / | / | / |
| Yamamoto et al./2019 | 2013–2018 | SC-RS | 5 | / | / | / | / | / | / | / | / | 0 | 0 | 5 (100) | / | / | / |
| Kim et al./2020 | 2004–2015 | SC-RS | 16 | 12 (75.0) | 4 (25.0) | 55.5 (42–73) | 9 (56.3) | 7 (43.7) | / | / | 3 (18.7) | 0 | 13 (81.3) | 0 | 0 | 4 (25.0) | |
| Sakamoto et al./2020 | 1986–2016 | SC-RS | 19 | 8 (42.1) | 11 (57.9) | 63 (46–74) | 0 | 9 (47.4) | 10 (52.6) | / | / | 10 (52.6) | 0 | 9 (47.4) | / | / | / |
CRC = Colorectal cancer; CEA = Carcinoembryonic antigen; CA 19.9 = Carbohydrate antigen 19.9; SC-RS = Single-center retrospective study. a = mean.